SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

Current Report Pursuant to Section 13 or 15(d) of the Securities Act of 1934

Date of Report: ~~June~~January 222, ~~2007~~2009

CLX ~~INVESTMENT COMPANY~~MEDICAL, INC.

(Exact Name of Registrant as Specified in its Charter)


Colorado	0-9392	84-0749623
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

29970 Technology Drive, Suite 203~~, Murrieta, CA 92563 (Address of principal executive offices)~~

~~43180~~Murrieta, ~~Business~~California ~~Park~~92563 ~~Dr.,~~ (Address ~~Suite~~of ~~202,~~principal ~~Temecula~~executive CAoffices) ~~92590~~

(former name or former address, if changed since last report)

Registrant's telephone number, including area code: (951) 677-6735

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[ ]

Written communications pursuant to Rule 425 under the Securities Act

[ ]

Soliciting material pursuant to Rule 14a-12 under the Exchange Act

[ ]

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act

[ ]

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act

ITEM 45.0102 ~~CHANGES~~DEPARTURE INOF ~~REGISTRANT’S~~DIRECTORS ~~CERTIFYING~~OR ~~ACCOUNTANT~~PRINCIPAL OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF PRINCIPAL OFFICER

~~(a)~~ On ~~June~~January 222, ~~2007~~2009, ~~CLX~~the ~~Investment~~Registrant ~~Company,~~accepted ~~Inc.~~the (resignation from Robert McCoy as the ~~“Company”)~~Registrant’s ~~dismissed~~Chairman HJof ~~Associates~~the &Board ~~Consultants,~~of ~~LLP~~Directors. Mr. McCoy will continue to serve as ~~independent~~a ~~auditors~~member ~~for~~of the ~~Company~~Board of Directors. ~~The~~Effective ~~decision~~on the same date to ~~dismiss~~fill HJthe ~~Associates~~vacancy &created ~~Consultants~~by Mr. McCoy’s resignation, ~~LLP~~the ~~and~~Registrant toappointed ~~seek~~Patrick ~~new~~Edgerton, ~~independent~~a ~~auditors~~member ~~was~~of ~~approved~~the byBoard of Directors, as the ~~Company~~Registrant’s Chairman of the Board of Directors.

~~The~~Biographical ~~reports~~Information ~~of HJ Associates & Consultants, LLP on the Company’s financial statements~~ for ~~the~~Patrick fiscal years ended September 30, 2006 and 2005 did not contain an adverse opinion or a disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope or accounting principles. In connection with the audits of the Company’s financial statements for the fiscal years ended September 30, 2006 and 2005, (1) there were no disagreements with HJ Associates & Consultants, LLP on any matter of accounting principles or practices, financial statement disclosure or auditing scope and procedure which, if not resolved to the satisfaction of HJ Associates & Consultants, LLP, would have caused HJ Associates & Consultants, LLP to make reference to the matter in its report and (2) there were no “reportable events” as that term is defined in Item 304 of Regulation S-K promulgated under the Securities Exchange Act of 1934 (“Item 304”).Edgerton

~~(b)~~From On1984 ~~June~~to ~~25,~~1997 ~~2007,~~Mr. ~~the~~Edgerton ~~Company~~served ~~engaged~~as ~~Gruber~~vice &president ~~Company,~~of ~~LLC~~various aspositions ~~the~~for ~~Company's~~McKesson, ~~independent~~vice ~~accountant~~president toof ~~report~~credit on(1984 ~~the~~to ~~Company’s~~1995); ~~balance~~vice ~~sheets~~president as of ~~September~~chain ~~30,~~development ~~2007,~~(1995 ~~and~~to ~~the~~1996); ~~related~~and ~~statements~~vice president of ~~income,~~national ~~stockholders’~~accounts ~~equity~~(1996 to 1997); he negotiated and ~~cash~~prepared ~~flows~~supply contracts for ~~the~~major ~~years~~drug ~~then~~companies, ~~ended.~~bringing ~~Neither~~in ~~the~~over ~~Company~~$500 ~~nor~~million ~~anyone~~of ~~acting~~new onbusiness ~~its~~in ~~behalf~~one ~~consulted~~year. From ~~with~~2000 ~~Gruber~~to ~~& Company~~2004, ~~LLC~~Mr. ~~regarding~~Edgerton ~~(i)~~served ~~either~~as ~~the~~chief ~~application~~executive officer of ~~any~~Sun ~~accounting~~Drug, ~~principles~~Inc., to a ~~specific~~retail ~~completed~~drug orbusiness, ~~contemplated~~and ~~transaction~~had ofpreviously ~~the~~spent ~~Company,~~two ordecades ~~the~~in ~~type~~a variety of ~~audit~~positions ~~opinion~~for ~~that~~McKesson ~~might~~Corporation, bea ~~rendered~~Fortune by15 ~~Gruber~~healthcare &services ~~Company~~and information technology company, ~~LLC~~culminating onin the ~~Company's~~position ~~financial~~of ~~statements;~~vice orpresident ~~(ii)~~of ~~any~~national ~~matter~~accounts. In ~~that~~this ~~was~~role, ~~either~~Mr. ~~the~~Edgerton ~~subject~~managed ofcustomers apurchasing ~~disagreement~~in ~~with~~excess HJof ~~Associates~~$1 &billion ~~Consultants,~~annually ~~LLP~~and orcalled aon ~~reportable~~major ~~event~~food ~~with~~and ~~respect~~drug chains to HJsecure ~~Associates~~new ~~& Consultants, LLP~~business.

~~ITEM~~Mr. 9Edgerton owns and has served as President and CEO of Edgerton Consulting since 1997.01 Edgerton ~~Financial~~Consulting ~~Statements~~provides consulting for business solutions in finance, marketing acquisitions, corporate restructuring, and ~~Exhibits~~general business practices. In October 2005, Mr. Edgerton was appointed as vice president of European/United States operations of Zonda, Incorporated, a majority owned subsidiary of CLX Medical, Inc., and since February 2006, he has served as Zonda's Chairman of the Board of Directors.

Exhibit No.	Document	Location
16.1	Letter dated June 25, 2007, from HJ Associates & Consultants, LLP to the Securities and Exchange Commission.	Filed herewith

SIGNATURES

~~SIGNATURES~~Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

~~Pursuant~~CLX ~~to the requirements of the Securities Exchange Act of 1934~~MEDICAL, ~~the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized~~INC.

CLX INVESTMENT COMPANY, INC.


January 5, 2009	/s/ Vera Leonard
Date	Vera Leonard, Chief Executive Officer

June 26, 2007	/s/ Robert McCoy
Date	Robert McCoy, Chief Executive Officer

Filing Compare · CLX MEDICAL, INC.